P068: Delivery of monogenic and polygenic results to inform cancer screening: The Prostate cancer, Genetic Risk and Equitable Screening Study (ProGRESS)

Prostate cancer (PCa) remains a leading cause of death in the US, partially due to the lack of optimal screening strategies to identify people at high risk. Current screening approaches, namely prostate-specific antigen (PSA) testing, do not differentiate men with low-grade PCa from those with clinically significant PCa. Tailoring screening strategies to an individual’s specific genetic profile may improve PCa screening effectiveness. Here we present the experience of returning monogenic and polygenic results for prostate cancer risk to men enrolled in ProGRESS, an ongoing national pragmatic randomized controlled trial of precision PCa screening.